In This Section      
 

J. Bill McEvoy, MB BCh, MHS

Ciccarone Center Research

Published By

J. Bill McEvoy, MB BCh, MHS

J. Bill McEvoy, MB BCh, MHS
McEvoy, J. Bill, MB BCH, MHS

J. Bill McEvoy, MB BCH, MHS, is an Assistant Professor of Medicine.

Landmark Articles

Subclinical cardiovascular disease in plaque psoriasis: association or causal link?

By: Shaharyar S, Warraich H, McEvoy JW, Oni E, Ali SS, Karim A, Jamal O, Blaha MJ, Blumenthal RS, Fialkow J, Cury R, Budoff MJ, Agatston AA, Nasir K.

Since patients with psoriasis have an increased burden of subclinical atherosclerosis and endothelial dysfunction, those with greater severity and/or disease duration should be targeted for primary screening for cardiovascular disease risk reduction.

Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids).

By: Elshazly MB, Martin SS, Blaha MJ, Joshi PH, Toth PP, McEvoy JW, Al-Hijji MA, Kulkarni KR, Kwiterovich PO, Blumenthal RS, Jones SR.
There is a significant patient-level discordance between non-HDL-C and LDL-C percentiles at lower LDL-C and higher triglyceride levels, which has implications for the treatment of high-risk patients.

Very large database of lipids: rationale and design.

By: Martin SS, Blaha MJ, Toth PP, Joshi PH, McEvoy JW, Ahmed HM, Elshazly MB, Swiger KJ, Michos ED, Kwiterovich PO, Kulkarni KR, Chimera J, Cannon CP, Blumenthal RS, Jones SR.
The Very Large Database of Lipids database is an ongoing protocol that harnesses de-identified data from the daily operations of a commercial lipid laboratory and provides an opportunity for collaboration and new knowledge generation through careful examination of granular lipid data on a large scale.

Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.

By: Chrispin J, Martin SS, Hasan RK, Joshi PH, Minder CM, McEvoy JW, Kohli P, Johnson AE, Wang L, Blaha MJ, Blumenthal RS.
Over the past 25?years, lipid-lowering therapies have been developed that are proven to not only lower cholesterol, but also to decrease adverse cardiovascular events and CVD mortality. This review highlights some key clinical trials encompassing several classes of lipid-lowering medications that have provided clinicians with an evidence-based framework for managing their patients’ cardiovascular risk.

Statin therapy for hyperlipidemia.

Friedewald estimated versus directly measured low-density lipoprotein cholesterol and treatment implications.

By: Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, Joshi PH, Kulkarni KR, Mize PD, Kwiterovich PO, Defilippis AP, Blumenthal RS, Jones SR.
This study discovered that, compared with direct measurement, the Friedewald equation tends to underestimate low-density lipoprotein cholesterol (LDL-C) and, therefore, warrants additional evaluation in high-risk patients. Achieving non-high-density lipoprotein cholesterol (HDL-C) targets are important to reach in the secondary prevention setting.

Non-HDL cholesterol, guideline targets, and population percentiles for secondary prevention in a clinical sample of 1.3 million adults: the very large database of lipids (VLDL-2 Study).

By: Elshazly MB, Martin SS, Blaha MJ, Joshi PH, Toth PP, McEvoy JW, Al-Hijji MA, Kulkarni KR, Kwiterovich PO, Blumenthal RS, Jones SR.
There is significant patient-level discordance between non-HDL-C and LDL-C percentiles at lower values of LDL-C and higher triglycerides. Current non-HDL-C cut-points for high-risk patients should be lowered to match percentiles of LDL-C cut-points. Relatively small absolute reductions in non-HDL-C cut-points result in substantial reclassification of patients to higher treatment categories with potential implications for risk assessment and treatment.

Metabolic Syndrome: understanding the epidemic in India and South Asia.

By: Blaha MJ, Tota-Maharaj R, McEvoy JW.

Cigarette smoking is associated with increased mortality in both the presence and absence of coronary artery calcification.

By: McEvoy JW, Blaha MJ, Rivera JJ, Budoff MJ, Khan AN, Shaw LJ, Berman DS, Raggi P, Min JK, Rumberger JA, Callister TQ, Blumenthal RS, Nasir K.

The aim of this study was to further explore the interplay between smoking status, coronary artery calcium (CAC), and all-cause mortality. Smoking is a risk factor for death across the entire spectrum of subclinical coronary atherosclerosis. Smokers with any CAC had significantly higher mortality than smokers without CAC, a finding with implications for smokers undergoing lung cancer CT-based screening. However, the absence of CAC might not be as useful a "negative risk factor" in active smokers, because this group has mortality rates similar to nonsmokers with mild-to-moderate atherosclerosis.

Mortality rates in smokers and nonsmokers in the presence or absence of coronary artery calcification.

By: McEvoy JW, Blaha MJ, Rivera JJ, Budoff MJ, Khan AN, Shaw LJ, Berman DS, Raggi P, Min JK, Rumberger JA, Callister TQ, Blumenthal RS, Nasir K.

The aim of this study was to further explore the interplay between smoking status, coronary artery calcium (CAC), and all-cause mortality. Smoking is a risk factor for death across the entire spectrum of subclinical coronary atherosclerosis. Smokers with any CAC had significantly higher mortality than smokers without CAC, a finding with implications for smokers undergoing lung cancer CT-based screening. However, the absence of CAC might not be as useful a "negative risk factor" in active smokers, because this group has mortality rates similar to nonsmokers with mild-to-moderate atherosclerosis.